Materialise Stock: A Tale of Two Divisions

Materialise NV, the pioneering force in 3D printing solutions, now trades on dual exchanges, yet its latest quarterly performance reveals a company at a crossroads. The third-quarter results for 2025 paint a picture of stark division, where one segment thrives while others face significant headwinds. Investors are left to ponder whether this signals an impending recovery or a period of sustained challenge.

For Q3 2025, Materialise reported consolidated revenue of €66.259 million, representing a 3.5 percent decrease compared to the same period last year. Net income settled at a modest €1.848 million, translating to €0.03 per share.

A deeper look into the segment performance reveals the core of the story:
* Medical Segment: A standout performer, surging 10.3 percent to €33.296 million.
* Software Segment: Declined by 7.4 percent.
* Manufacturing Segment: Experienced a sharp contraction of 17.1 percent.

The medical division's robust growth served as a crucial counterbalance, partially offsetting the pronounced weaknesses elsewhere. An additional key metric underscores the stability of one revenue stream: recurring software revenues accounted for a significant 83 percent of the total software business.

Should investors sell immediately? Or is it worth buying Materialise?

Dual Listing Strategy and Insider Trading Activity

In a strategic move to broaden its investor base, Materialise commenced trading on Euronext Brussels this past Friday. This new listing complements its existing presence on the Nasdaq. Importantly, this was not a capital-raising event, as no new shares were issued.

A notable development accompanying the dual listing involves the company's founders. Fried Vancraen and Hilde Ingelaere intend to sell up to 590,000 shares through the Brussels exchange, a transaction equating to approximately one percent of the outstanding shares. Concurrently, they are considering the purchase of American Depositary Shares on the Nasdaq. This simultaneous selling and potential buying across different exchanges presents an unconventional maneuver that has captured market attention.

Technical Outlook and Annual Guidance

Despite a 2.05 percent share price increase to $5.97 on Friday, technical indicators for Materialise stock continue to flash cautionary signals. Trading activity remained subdued, with a volume of only around 109,000 shares changing hands.

The critical question for investors is whether the company can maintain its full-year outlook. Management has reaffirmed its 2025 guidance, projecting an adjusted EBIT between €6 million and €10 million on expected revenue in the range of €265 million to €280 million. The sustainability of this forecast hinges on a single, pivotal factor: the ability of the strong medical segment to provide sufficient support to counterbalance the ongoing struggles in manufacturing and software.